---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-110066"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:23:16.502266+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences enters $50M ATM equity offering with Jefferies for cytisinicline

## Summary
- Entered Open Market Sale Agreement with Jefferies for at-the-market offering of up to $50M of common stock.
- Jefferies receives up to 3% commission; company has no obligation to sell and may suspend at any time.
- Proceeds to fund clinical development of cytisinicline for smoking cessation and general corporate purposes.
- Offering made under existing S-3 registration statement filed June 28, 2024.

## SEC filing metadata
- accession: 0000950170-24-110066
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017024110066/0000950170-24-110066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017024110066/achv-20240927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-110066
- JSON: https://secwatch.observer/filing/0000950170-24-110066.json
- Plain text: https://secwatch.observer/filing/0000950170-24-110066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.